An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2018
At a glance
- Drugs IONIS-SOD1Rx (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Biogen
- 13 Aug 2018 Planned End Date changed from 1 Jan 2020 to 31 Jan 2020.
- 13 Aug 2018 Planned primary completion date changed from 1 Jan 2020 to 31 Jan 2020.
- 13 Apr 2017 Status changed from not yet recruiting to recruiting.